Different inhibitors for the same target in metastatic luminal breast cancer: Is there any difference?

Elie El Rassy, Ziad Bakouny, Tarek Assi, Joseph Kattan

Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

6 Citations (Scopus)

Résumé

Aim: To determine which of the CDK4/6 inhibitors is the optimal treatment in metastatic luminal breast cancer. Materials & methods: A network meta-analysis using the frequentist approach and generalized pairwise modeling was computed. Results: The associations of aromatase inhibitor with ribociclib, palbociclib and abemaciclib were similar in efficacy. Palbociclib-based regimen was associated with significantly lower treatment discontinuation rates compared with the other approved drugs in this indication. Conclusion: In the absence of direct comparative evidence, the results of this network meta-analysis represent the best available evidence for decision making in the first-line treatment of metastatic luminal breast cancer.

langue originaleAnglais
Pages (de - à)891-895
Nombre de pages5
journalFuture Oncology
Volume14
Numéro de publication9
Les DOIs
étatPublié - 1 avr. 2018
Modification externeOui

Contient cette citation